Fig. 5
From: Rescue of cognitive deficits in APP/PS1 mice by accelerating the aggregation of β-amyloid peptide
ZGM1 increases the number of Aβ plaques and Aβ42 content in APP/PS1 mice. APP/PS1 and WT mice subjected to behavioral tests were also subjected to brain analyses (n = 10~12). ZGM1 at 0 (TG (TG), male), 40 (TG (LZ), male), or 120 mg kg− 1 per day (TG (HZ), male) was given to 4-month-old APP/PS1 for 2 months, and their brains were compared with age-matched WT brains (WT(W), male). a, c ThS-stained Aβ plaques in the hippocampal or cerebral cortex region (scale bars, 500 mm) of each group. Each column of pictures shows the plaque levels of different individuals within the same group to show the individual differences. b, d Number or relative total area in the hippocampal or cerebral cortex region. b Hippocampal region. Number from left to right: P = 3.87E−07, 0.0040, 0.0087. Relative total area from left to right: P = 1.05E−07, 0.00022, 0.00044. d Cerebral cortex region number from left to right: P = 1.09E−10, 0.00039, 0.00061. Relative total area from left to right: P = 3.00E−09, 0.0071, 0.0042. e, f ELISA of Aβ40 (e) (P = 1.17E−05) and Aβ42 (f) in total brain lysates (P = 1.07E−08, 0.021, 0.027). g Western blotting analyses of APP expression in total brain lysates (detected at ~ 100 kDa by 6E10 antibody). The error bars represent the S.E.M. One-way analysis of variance was performed (*P < 0.05, **P < 0.01, ***P < 0.001; n/s were not significant)